US Stock MarketDetailed Quotes

GSK GlaxoSmithKline

Watchlist
  • 38.645
  • +0.695+1.83%
Trading Mar 4 13:53 ET
78.79BMarket Cap24.46P/E (TTM)

GlaxoSmithKline Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2024
(Q4)Dec 31, 2024
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
Total revenue
3.46%31.38B
0.81%8.12B
-1.66%8.01B
9.84%7.88B
5.93%7.36B
3.42%30.33B
9.16%8.05B
4.06%8.15B
3.59%7.18B
-3.32%6.95B
Operating revenue
3.46%31.38B
0.81%8.12B
-1.66%8.01B
9.84%7.88B
5.93%7.36B
3.42%30.33B
9.16%8.05B
4.06%8.15B
3.59%7.18B
-3.32%6.95B
Cost of revenue
5.64%9.05B
5.83%2.56B
5.50%2.4B
9.83%2.12B
1.39%1.97B
-10.35%8.57B
8.04%2.42B
-6.23%2.27B
-11.21%1.93B
-28.49%1.94B
Gross profit
2.60%22.33B
-1.35%5.56B
-4.43%5.62B
9.84%5.76B
7.69%5.39B
10.08%21.76B
9.65%5.63B
8.68%5.88B
10.37%5.25B
11.96%5.01B
Operating expense
16.42%16.79B
-25.11%3.34B
38.21%5.43B
32.56%4.12B
33.39%3.9B
10.56%14.42B
50.00%4.46B
-6.86%3.93B
-15.44%3.11B
34.22%2.93B
Selling and administrative expenses
17.37%11.02B
-0.56%2.66B
65.51%3.8B
8.69%2.47B
-2.61%2.09B
12.10%9.39B
9.84%2.68B
11.67%2.3B
9.78%2.27B
18.27%2.14B
-General and administrative expense
17.37%11.02B
-0.56%2.66B
65.51%3.8B
8.69%2.47B
-2.61%2.09B
12.10%9.39B
9.84%2.68B
11.67%2.3B
9.78%2.27B
18.27%2.14B
Research and development costs
2.86%6.4B
-0.78%2.03B
-7.37%1.46B
10.14%1.48B
13.81%1.43B
13.39%6.22B
13.91%2.05B
17.01%1.58B
7.97%1.34B
14.23%1.26B
Other operating expenses
--9M
---1.18B
-8.72%335M
--318M
--533M
----
----
-65.64%367M
----
----
Operating profit
-24.55%5.54B
89.00%2.22B
-90.30%189M
-23.12%1.65B
-28.43%1.49B
9.15%7.35B
-45.79%1.17B
63.64%1.95B
98.06%2.14B
-9.20%2.08B
Net non-operating interest income expense
17.96%-603M
22.31%-195M
21.52%-124M
1.32%-150M
22.99%-134M
11.02%-735M
5.99%-251M
11.24%-158M
16.94%-152M
12.12%-174M
Non-operating interest income
25.00%60M
26.32%-28M
33.33%32M
-27.27%24M
10.34%32M
54.84%48M
-100.00%-38M
9.09%24M
57.14%33M
314.29%29M
Non-operating interest expense
-11.72%640M
-7.10%144M
-14.29%156M
-5.95%174M
-18.23%166M
-12.23%725M
-28.57%155M
-9.00%182M
-9.31%185M
-0.98%203M
Total other finance cost
-60.34%23M
----
----
----
----
87.10%58M
----
----
----
----
Other net income (expense)
Special income (charges)
-75.14%-1.23B
-74.89%-1.23B
--0
--0
--0
42.81%-704M
42.73%-705M
--0
--0
--1M
-Less：Restructuring and merger&acquisition
121.37%1.75B
----
----
----
----
-50.78%791M
----
----
----
----
-Less:Other special charges
-495.40%-518M
----
----
----
----
76.86%-87M
---86M
----
----
---1M
Income before tax
-42.66%3.48B
48.55%563M
-96.43%64M
-24.76%1.5B
-28.95%1.36B
7.75%6.06B
-76.69%379M
76.98%1.79B
121.76%1.99B
-8.93%1.91B
Income tax
-30.42%526M
426.32%62M
-100.39%-1M
-21.07%191M
-0.72%274M
6.93%756M
-2,000.00%-19M
10.30%257M
61.33%242M
-14.55%276M
Net income
-44.40%2.95B
25.88%501M
-95.76%65M
-25.27%1.3B
-33.72%1.08B
-66.02%5.31B
-75.43%398M
-85.87%1.53B
78.97%1.75B
-24.73%1.63B
Net income continuous Operations
-44.40%2.95B
25.88%501M
-95.76%65M
-25.27%1.3B
-33.72%1.08B
7.86%5.31B
-75.51%398M
96.92%1.53B
133.91%1.75B
-7.91%1.63B
Net income discontinuous operations
--0
----
----
----
----
--0
----
----
----
----
Minority interest income
-1.05%376M
81.25%87M
75.71%123M
8.26%131M
-75.18%35M
-42.86%380M
-61.60%48M
84.21%70M
-11.68%121M
-61.37%141M
Net income attributable to the parent company
-47.75%2.58B
18.29%414M
-103.96%-58M
-27.77%1.17B
-29.80%1.05B
-67.05%4.93B
-76.59%350M
-86.47%1.46B
93.79%1.62B
-17.31%1.49B
Preferred stock dividends
Other preferred stock dividends
0
0
0
0
0
0
0
0
0
0
Net income attributable to common stockholders
-47.75%2.58B
18.29%414M
-103.96%-58M
-27.77%1.17B
-29.80%1.05B
-67.05%4.93B
-76.59%350M
-86.47%1.46B
93.79%1.62B
-17.31%1.49B
Basic earnings per share
-48.03%1.264
17.44%0.202
-103.88%-0.028
-28.18%0.576
-30.16%0.514
-67.26%2.432
-76.82%0.172
-86.55%0.722
140.99%0.802
-18.04%0.736
Diluted earnings per share
-48.12%1.244
17.65%0.2
-103.93%-0.028
-28.21%0.57
-30.41%0.508
-67.26%2.398
-76.71%0.17
-86.55%0.712
140.90%0.794
-17.79%0.73
Dividend per share
8.15%1.217
5.45%0.296
10.70%0.2992
3.82%0.3019
12.82%0.3198
-25.33%1.1253
0.16%0.2807
-14.72%0.2703
-15.84%0.2908
-49.75%0.2835
Currency Unit
GBP
GBP
GBP
GBP
GBP
GBP
GBP
GBP
GBP
GBP
Accounting Standards
NonUS-GAAP
NonUS-GAAP
NonUS-GAAP
NonUS-GAAP
NonUS-GAAP
NonUS-GAAP
NonUS-GAAP
NonUS-GAAP
NonUS-GAAP
NonUS-GAAP
Audit Opinions
--
--
--
--
--
Unqualified Opinion
--
--
--
--
(FY)Dec 31, 2024(Q4)Dec 31, 2024(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023
Total revenue 3.46%31.38B0.81%8.12B-1.66%8.01B9.84%7.88B5.93%7.36B3.42%30.33B9.16%8.05B4.06%8.15B3.59%7.18B-3.32%6.95B
Operating revenue 3.46%31.38B0.81%8.12B-1.66%8.01B9.84%7.88B5.93%7.36B3.42%30.33B9.16%8.05B4.06%8.15B3.59%7.18B-3.32%6.95B
Cost of revenue 5.64%9.05B5.83%2.56B5.50%2.4B9.83%2.12B1.39%1.97B-10.35%8.57B8.04%2.42B-6.23%2.27B-11.21%1.93B-28.49%1.94B
Gross profit 2.60%22.33B-1.35%5.56B-4.43%5.62B9.84%5.76B7.69%5.39B10.08%21.76B9.65%5.63B8.68%5.88B10.37%5.25B11.96%5.01B
Operating expense 16.42%16.79B-25.11%3.34B38.21%5.43B32.56%4.12B33.39%3.9B10.56%14.42B50.00%4.46B-6.86%3.93B-15.44%3.11B34.22%2.93B
Selling and administrative expenses 17.37%11.02B-0.56%2.66B65.51%3.8B8.69%2.47B-2.61%2.09B12.10%9.39B9.84%2.68B11.67%2.3B9.78%2.27B18.27%2.14B
-General and administrative expense 17.37%11.02B-0.56%2.66B65.51%3.8B8.69%2.47B-2.61%2.09B12.10%9.39B9.84%2.68B11.67%2.3B9.78%2.27B18.27%2.14B
Research and development costs 2.86%6.4B-0.78%2.03B-7.37%1.46B10.14%1.48B13.81%1.43B13.39%6.22B13.91%2.05B17.01%1.58B7.97%1.34B14.23%1.26B
Other operating expenses --9M---1.18B-8.72%335M--318M--533M---------65.64%367M--------
Operating profit -24.55%5.54B89.00%2.22B-90.30%189M-23.12%1.65B-28.43%1.49B9.15%7.35B-45.79%1.17B63.64%1.95B98.06%2.14B-9.20%2.08B
Net non-operating interest income expense 17.96%-603M22.31%-195M21.52%-124M1.32%-150M22.99%-134M11.02%-735M5.99%-251M11.24%-158M16.94%-152M12.12%-174M
Non-operating interest income 25.00%60M26.32%-28M33.33%32M-27.27%24M10.34%32M54.84%48M-100.00%-38M9.09%24M57.14%33M314.29%29M
Non-operating interest expense -11.72%640M-7.10%144M-14.29%156M-5.95%174M-18.23%166M-12.23%725M-28.57%155M-9.00%182M-9.31%185M-0.98%203M
Total other finance cost -60.34%23M----------------87.10%58M----------------
Other net income (expense)
Special income (charges) -75.14%-1.23B-74.89%-1.23B--0--0--042.81%-704M42.73%-705M--0--0--1M
-Less：Restructuring and merger&acquisition 121.37%1.75B-----------------50.78%791M----------------
-Less:Other special charges -495.40%-518M----------------76.86%-87M---86M-----------1M
Income before tax -42.66%3.48B48.55%563M-96.43%64M-24.76%1.5B-28.95%1.36B7.75%6.06B-76.69%379M76.98%1.79B121.76%1.99B-8.93%1.91B
Income tax -30.42%526M426.32%62M-100.39%-1M-21.07%191M-0.72%274M6.93%756M-2,000.00%-19M10.30%257M61.33%242M-14.55%276M
Net income -44.40%2.95B25.88%501M-95.76%65M-25.27%1.3B-33.72%1.08B-66.02%5.31B-75.43%398M-85.87%1.53B78.97%1.75B-24.73%1.63B
Net income continuous Operations -44.40%2.95B25.88%501M-95.76%65M-25.27%1.3B-33.72%1.08B7.86%5.31B-75.51%398M96.92%1.53B133.91%1.75B-7.91%1.63B
Net income discontinuous operations --0------------------0----------------
Minority interest income -1.05%376M81.25%87M75.71%123M8.26%131M-75.18%35M-42.86%380M-61.60%48M84.21%70M-11.68%121M-61.37%141M
Net income attributable to the parent company -47.75%2.58B18.29%414M-103.96%-58M-27.77%1.17B-29.80%1.05B-67.05%4.93B-76.59%350M-86.47%1.46B93.79%1.62B-17.31%1.49B
Preferred stock dividends
Other preferred stock dividends 0000000000
Net income attributable to common stockholders -47.75%2.58B18.29%414M-103.96%-58M-27.77%1.17B-29.80%1.05B-67.05%4.93B-76.59%350M-86.47%1.46B93.79%1.62B-17.31%1.49B
Basic earnings per share -48.03%1.26417.44%0.202-103.88%-0.028-28.18%0.576-30.16%0.514-67.26%2.432-76.82%0.172-86.55%0.722140.99%0.802-18.04%0.736
Diluted earnings per share -48.12%1.24417.65%0.2-103.93%-0.028-28.21%0.57-30.41%0.508-67.26%2.398-76.71%0.17-86.55%0.712140.90%0.794-17.79%0.73
Dividend per share 8.15%1.2175.45%0.29610.70%0.29923.82%0.301912.82%0.3198-25.33%1.12530.16%0.2807-14.72%0.2703-15.84%0.2908-49.75%0.2835
Currency Unit GBPGBPGBPGBPGBPGBPGBPGBPGBPGBP
Accounting Standards NonUS-GAAPNonUS-GAAPNonUS-GAAPNonUS-GAAPNonUS-GAAPNonUS-GAAPNonUS-GAAPNonUS-GAAPNonUS-GAAPNonUS-GAAP
Audit Opinions ----------Unqualified Opinion--------
Trending Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks

Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.

Symbol Mini Chart % Chg
Bit Origin
BTOG
+21.36%
Argo Blockchain
ARBK
+19.17%
Bit Digital
BTBT
+5.63%
Bitdeer Technologies
BTDR
+5.04%
Bitfarms
BITF
+4.25%

Unlock the Full List

Investment Theme Infectious Disease
Infectious Disease
Intraday+0.10%
CAR-T Therapy
CAR-T Therapy
Intraday-0.07%